Pamela Booth Davis

US Patent:

6770739, Aug 3, 2004

Filed:

Feb 24, 2000

Appl. No.:

09/512260

Inventors:

Lynn Adams - Cleveland Heights OH
Pamela B. Davis - Cleveland Heights OH
Jian Jie Ma - Highland Heights OH

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

C07K 1400

US Classification:

530300, 530350, 536 234

Abstract:

Phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) is essential for opening the CFTR chloride channel. A short segment containing many negatively charged amino acids (817-838, NEG2) within the regulatory (R) domain of CFTR is a critical regulator of the chloride channel activity. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of the chloride channel. Exogenous NEG2 peptide interacts with the CFTR molecule and exhibits stimulatory effects on CFTR function. Our data suggest that NEG2 interacts with other cytosolic domains of CFTR to control the opening transitions of the chloride channel.

US Patent:

6810883, Nov 2, 2004

Filed:

Nov 8, 2002

Appl. No.:

10/290402

Inventors:

John Louis Felter - Chester VA
Robert E. Lee - Richmond VA
Ashok Solanky - Mechanicsville VA
Clint Blake - Mechanicsville VA
Pamela Davis - Glen Allen VA
David E. Sharpe - Chesterfield VA
Mark E. Watson - Mechanicsville VA
Robert L. Ripley - Midlothian VA
Brett W. Stevenson - Richmond VA
William J. Crowe - Chester VA

Assignee:

Philip Morris USA Inc. - New York NY

International Classification:

A24F 1304

US Classification:

131194, 131328, 131329

Abstract:

An electrically heated cigarette smoking device includes a heater unit, heater blades for applying heat to portions of a cigarette that is supported within the heater unit, the heater unit having an opening adapted to receive an end of a cigarette and adapted to position the end of the cigarette in proximity to the heater blades, and the heater unit defining at least part of a suction flow passage through which ambient air is drawn into contact with the cigarette when a smoker draws on the cigarette positioned in the heater unit. The heater unit is mounted within a partition that positions the heater unit relative to the housing and at least partially defines a bypass flow passage in fluid communication with ambient air surrounding the housing, the partition further defining a flow diverting passage leading from the bypass flow passage to the suction flow passage and through which ambient air is drawn from the bypass flow passage when a smoker puffs on a cigarette inserted in the heater unit opening. A flow sensor is positioned in the flow diverting passage to provide a signal indicative of a smoker taking a puff on the cigarette.

US Patent:

D660672, May 29, 2012

Filed:

Aug 17, 2011

Appl. No.:

29/399700

Inventors:

Pamela S. Davis - Akron OH, US

International Classification:

0804

US Classification:

D 8 86

US Patent:

D677146, Mar 5, 2013

Filed:

Aug 17, 2011

Appl. No.:

29/399698

Inventors:

Pamela S. Davis - Akron OH, US

International Classification:

0808

US Classification:

D 8387

US Patent:

D690193, Sep 24, 2013

Filed:

Sep 21, 2012

Appl. No.:

29/432839

Inventors:

Pamela S. Davis - Akron OH, US

Assignee:

Fastener Technology, Inc. - Akron OH

International Classification:

0808

US Classification:

D 8399

US Patent:

20030100501, May 29, 2003

Filed:

Sep 23, 2002

Appl. No.:

10/252012

Inventors:

Pamela Davis - Cleveland Heights OH, US
Jianjie Ma - Belle Mead NJ, US
Thomas Gerken - Solon OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K038/17
C07K014/705

US Classification:

514/012000, 530/350000

Abstract:

Phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) is essential for opening the CFTR chloride channel. A short segment containing many negatively charged amino acids (817-838, NEG2) within the regulatory (R) domain of CFTR is a critical regulator of the chloride channel activity. An isolated NEG2 polypeptide may be expressed as a separate sequence that stimulates CFTR channel openings at lower concentrations, but that inhibits CFTR channel openings at higher concentrations. Residues in the NEG2 sequence were substituted to produce a polypeptide that exerts only an activating effect on CFTR. One such polypeptide is the Q4N2NEG2 polypeptide. Exogenous Q4N2NEG2 exerts stimulatory effects on both wild-type and mutant G551D CFTR function, without exhibiting inhibitory activity at any concentration.

US Patent:

20040121957, Jun 24, 2004

Filed:

Dec 23, 2003

Appl. No.:

10/743381

Inventors:

Lynn Adams - Cleveland Heights OH, US
Pamela Davis - Cleveland Heights OH, US
Jian Ma - Highland Heights OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K038/17
C07K014/705

US Classification:

514/012000, 514/013000, 514/014000, 514/015000, 530/350000

Abstract:

Phosphorylation of the cystic fibrosis transmembrane conductance regulator (CFTR) by cyclic AMP-dependent protein kinase (PKA) is essential for opening the CFTR chloride channel. A short segment containing many negatively charged amino acids (817-838, NEG2) within the regulatory (R) domain of CFTR is a critical regulator of the chloride channel activity. Deletion of NEG2 from CFTR completely eliminates the PKA dependence of the chloride channel. Exogenous NEG2 peptide interacts with the CFTR molecule and exhibits stimulatory effects on CFTR function. Our data suggest that NEG2 interacts with other cytosolic domains of CFTR to control the opening transitions of the chloride channel.

US Patent:

20040152653, Aug 5, 2004

Filed:

Nov 7, 2003

Appl. No.:

10/703206

Inventors:

Assem Ziady - Cleveland OH, US
Pamela Davis - Cleveland OH, US
Thomas Ferkol - Cleveland OH, US
Alfred Malouf - Cleveland OH, US

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K048/00

US Classification:

514/044000

Abstract:

Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. Any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins, pharmacological agents, or nucleic acids, as well as carrier molecules, and ligands for the receptors. The ligands can be coupled directly to the therapeutic agent or to a carrier molecule which binds to the therapeutic agent.